Nothing Special   »   [go: up one dir, main page]

EP0617621A4 - Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit. - Google Patents

Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit.

Info

Publication number
EP0617621A4
EP0617621A4 EP92903432A EP92903432A EP0617621A4 EP 0617621 A4 EP0617621 A4 EP 0617621A4 EP 92903432 A EP92903432 A EP 92903432A EP 92903432 A EP92903432 A EP 92903432A EP 0617621 A4 EP0617621 A4 EP 0617621A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical activity
cholecystokinin antagonists
central
central cholecystokinin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92903432A
Other languages
English (en)
French (fr)
Other versions
EP0617621A1 (de
Inventor
David Christopher Horwell
John Hughes
Geoff Neil Woodruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to EP96200242A priority Critical patent/EP0729752A2/de
Publication of EP0617621A1 publication Critical patent/EP0617621A1/de
Publication of EP0617621A4 publication Critical patent/EP0617621A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP92903432A 1991-12-20 1991-12-20 Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit. Withdrawn EP0617621A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96200242A EP0729752A2 (de) 1991-12-20 1991-12-20 Zentrale Cholecystokininantagonisten mit pharmazeutischer Wirksamkeit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/009555 WO1993012791A1 (en) 1991-12-20 1991-12-20 Central cholecystokinin antagonists having pharmaceutical activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP96200242A Division EP0729752A2 (de) 1991-12-20 1991-12-20 Zentrale Cholecystokininantagonisten mit pharmazeutischer Wirksamkeit

Publications (2)

Publication Number Publication Date
EP0617621A1 EP0617621A1 (de) 1994-10-05
EP0617621A4 true EP0617621A4 (de) 1995-04-05

Family

ID=22226062

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92903432A Withdrawn EP0617621A4 (de) 1991-12-20 1991-12-20 Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit.

Country Status (3)

Country Link
EP (1) EP0617621A4 (de)
JP (1) JPH07507993A (de)
WO (1) WO1993012791A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618812A (en) * 1992-07-29 1997-04-08 Merck Sharp & Dohme, Ltd. Benzodiazepine derivatives
FR2744362B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744361B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744363B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
TW442449B (en) 1996-07-04 2001-06-23 Hoechst Ag Process for preparing 1,2-dichloroethane by direct chlorination
EP1183242A2 (de) 1999-05-26 2002-03-06 Du Pont Pharmaceuticals Company Als hemmer der reversen transcriptase von hiv verwendbare 1,4-benzodiazepin-2-one
EP1749525A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Zusammensetzung enthaltend substituierte Pyrazoline und gegen Sucht wirksame Mittel
ES2319074B1 (es) * 2005-07-15 2009-12-03 Laboratorios Del Dr. Esteve, S.A. Combinacion de principios activos.
US8247438B2 (en) 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (de) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomainhemmer und ihre verwendung
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
PT3157928T (pt) 2014-06-20 2019-05-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411668A2 (de) * 1989-08-04 1991-02-06 MERCK SHARP & DOHME LTD. Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663771A (en) * 1971-01-12 1972-05-16 Gulf & Western Industries Distributor rotor with improved contact securing means
NZ212436A (en) * 1984-06-25 1989-04-26 Rotta Research Lab D,l-glutamic and d,l-aspartic acid derivatives and pharmaceutical compositions
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
IT1215169B (it) * 1985-12-17 1990-01-31 Rotta Research Lab Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione
IE904560A1 (en) * 1989-12-18 1991-06-19 Merck & Co Inc New benzodiazepine analogs
CA2032226A1 (en) * 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepine analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411668A2 (de) * 1989-08-04 1991-02-06 MERCK SHARP & DOHME LTD. Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9312791A1 *

Also Published As

Publication number Publication date
WO1993012791A1 (en) 1993-07-08
JPH07507993A (ja) 1995-09-07
EP0617621A1 (de) 1994-10-05

Similar Documents

Publication Publication Date Title
GR3018318T3 (en) Pharmaceutical agents.
PL297747A1 (en) Prolonged action pharmaceutical dosage forms
PH31205A (en) Pharmaceutical composition.
EP0670716A4 (de) Geschmacksmaskierte pharmazeutische substanzen.
ZA926020B (en) Pharmaceutical combination formulation.
GR3036937T3 (en) Pharmaceutical formulations.
ZA92600B (en) Lhrh antagonists
GR3032366T3 (en) Pharmaceutical cyclosporin composition.
EP0673247A4 (de) Fibrinogen rezeptor antagonisten.
EP0667773A4 (de) Fibrinogen-rezeptor-antagonisten.
FI922252A0 (fi) Farmaceutisk sammansaettning.
ZA927562B (en) Medicament.
PH31071A (en) Substituted pyrridopyrimidines useful antgiotensinII antagonists.
EP0617621A4 (de) Zentrale cholecystokininantagonisten mit pharmazeutischer wirksamkeit.
ZA9110018B (en) 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity.
OA09810A (en) Pharmaceutical composition.
ZA92110B (en) Pharmaceutical compositions.
GB9102727D0 (en) Pharmaceutical agent
ZA927506B (en) New drug formulation.
AU113462S (en) Dosage center
EP0600754A3 (de) Pharmazeutische Infusionseinrichtung mit konstantem Durchfluss.
ZA927369B (en) Pharmaceutical compositions.
ZA939626B (en) Pharmaceutical compounds.
ZA922586B (en) Cholecystokinin antagonists
ZA929916B (en) Therapeutic agents.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950210

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980630

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981111